Akèy › Lekemi Prolimfositik Selil-T
Etid klinik pou Lekemi Prolimfositik Selil-T ap rekrite nan Etazini
7 etid pou Lekemi Prolimfositik Selil-T ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05010005Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07311746Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 17, 2026 · NCT06810778A Registry for People With T-cell Lymphoma
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 20, 2026 · NCT05978141Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT07356245A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT04496349Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.